XENE
HealthcareXenon Pharmaceuticals Inc. · Biotechnology · $4B
What is Xenon Pharmaceuticals Inc.?
Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for neurological disorders, particularly epilepsy. Headquartered in Burnaby, Canada, the company is building a pipeline of ion-channel-targeted therapies.
Xenon Pharmaceuticals discovers and develops drug candidates that target ion channels in the nervous system — specifically potassium and sodium channels linked to epilepsy and related conditions. The company does not yet generate product revenue; it advances candidates through clinical trials and funds development partly through collaboration agreements with larger pharmaceutical partners. Its business model relies on licensing deals and milestone payments rather than commercial sales.
Xenon Pharmaceuticals was incorporated in 1996 and is based in Burnaby, Canada.
- XEN496 — Kv7 potassium channel opener in Phase III for KCNQ2 epilepsy encephalopathy
- XEN1101 — Kv7 opener in Phase II for epilepsy and other neurological disorders
- NBI-921352 — selective Nav1.6 inhibitor in Phase II for SCN8A epileptic encephalopathy
- XEN007 — CNS calcium channel modulator in Phase II trials
- Collaboration with Neurocrine Biosciences for epilepsy treatment development
Is XENE a Good Stock to Buy?
UQS Score rates XENE as Poor overall, reflecting the early-stage nature of its pipeline and the financial profile typical of pre-revenue biotech companies.
The Risk pillar stands out as the relative bright spot in XENE's profile — suggesting the company carries a more manageable near-term risk profile than many clinical-stage peers. This may reflect balance-sheet positioning or the structured nature of its collaboration agreements.
Quality, Moat, and Growth pillars all register as Weak, consistent with a company that has no approved products and no recurring revenue. The Valuation pillar reads as Elevated, meaning the market is pricing in significant future success.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does XENE pay dividends?
No — Xenon Pharmaceuticals Inc. does not currently pay a dividend.
XENE does not pay a dividend, which is standard for clinical-stage biopharmaceutical companies. Available capital is directed toward funding clinical trials and advancing the pipeline toward potential regulatory approval. Investors in XENE are typically seeking long-term capital appreciation tied to pipeline milestones rather than income.
When does XENE report earnings?
Xenon Pharmaceuticals reports financial results on a quarterly cadence, consistent with US- and Canada-listed equities.
As a pre-revenue company, quarterly reports focus on cash runway, clinical trial progress, and collaboration milestone updates rather than traditional revenue or profit metrics. Pipeline readouts and partnership developments tend to move the stock more than earnings beats or misses.
For the most recent quarter's results and management commentary, visit Xenon Pharmaceuticals' investor relations page directly.
XENE Price History
+205.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Xenon Pharmaceuticals Inc.?
Based on Xenon Pharmaceuticals Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
XENE Long-term Outlook
The fundamental outlook for XENE is closely tied to clinical trial outcomes rather than organic revenue growth. With Growth and Quality pillars both rated Weak, near-term financial improvement depends heavily on pipeline progression and potential partnership milestones. The Elevated Valuation pillar suggests the current share price already reflects optimistic assumptions about future approvals, leaving limited margin for clinical setbacks.
Growth drivers
- Advancement of XEN496 through Phase III trials toward a potential regulatory filing
- Milestone and royalty payments from the Neurocrine Biosciences collaboration
- Expansion of XEN1101 into additional neurological indications beyond epilepsy
Key risks
- Clinical trial failure or delay in any lead program could significantly impair the investment case
- Elevated valuation leaves little buffer if pipeline timelines slip
- Ongoing cash consumption with no product revenue creates funding dependency
XENE vs Peers
XENE operates in a competitive rare-disease and neurology space alongside other specialty and clinical-stage biopharmaceutical companies.
Terns focuses on metabolic and oncology indications rather than neurology, representing a different therapeutic-area bet within the clinical-stage biotech universe.
Ligand operates a royalty-based business model across multiple partners, offering a more diversified revenue profile compared to Xenon's single-pipeline focus.
Amicus targets rare metabolic and lysosomal storage diseases and has a more advanced commercial presence than Xenon's fully pre-revenue pipeline.
Frequently Asked Questions
What does Xenon Pharmaceuticals do?
Xenon Pharmaceuticals is a clinical-stage biotech company developing treatments for neurological disorders, with a focus on epilepsy. Its pipeline targets ion channels — potassium, sodium, and calcium — that play a role in seizure activity. The company has no approved products yet and funds operations through collaboration agreements and capital markets.
Does XENE pay dividends?
No, XENE does not pay a dividend. Clinical-stage biopharmaceutical companies typically reinvest all available capital into research and development. Investors in XENE are generally seeking returns through pipeline success and share price appreciation rather than income.
When does XENE report earnings?
Xenon Pharmaceuticals reports on a quarterly cadence. Because the company has no product revenue, reports center on cash position, trial updates, and collaboration milestones. Check Xenon Pharmaceuticals' investor relations page for the current reporting schedule.
Is XENE a good stock to buy?
UQS Score rates XENE as Poor overall, driven by Weak scores across Quality, Moat, and Growth pillars. The Risk pillar is the relative strength. Whether XENE fits a portfolio depends on an investor's risk tolerance for pre-revenue biotech and their view on the pipeline's clinical prospects. The full pillar breakdown is available to UQS Pro members.
Is XENE overvalued?
The UQS Valuation pillar for XENE is rated Elevated, suggesting the current market price reflects optimistic assumptions about future clinical and commercial success. For a company with no approved products, valuation is inherently speculative and sensitive to trial outcomes.
How does XENE compare to its competitors?
Compared to peers like Ligand Pharmaceuticals and Amicus Therapeutics, XENE is at an earlier commercial stage with no approved products. Ligand has a diversified royalty model, and Amicus has a commercial footprint in rare diseases. XENE's differentiation lies in its ion-channel biology expertise and its Neurocrine Biosciences partnership.
What is XENE's market cap bracket?
XENE is classified as a mid-cap stock. This places it in a range that is larger than most micro-cap clinical biotechs but well below large-cap pharmaceutical companies with established commercial products.
Who founded Xenon Pharmaceuticals?
Xenon Pharmaceuticals was incorporated in 1996. Founding details are publicly available through the company's official filings and investor relations materials for those seeking the full corporate history.
Is XENE a long-term quality investment?
As a long-term quality indicator, UQS rates XENE as Poor. The Weak Quality and Moat pillars reflect the absence of durable competitive advantages and recurring revenues typical of established pharmaceutical companies. Long-term value creation depends entirely on whether pipeline candidates reach approval and commercialization.
What is the main competitive advantage of Xenon Pharmaceuticals?
Xenon's differentiation lies in its specialized expertise in ion-channel biology, which underpins its entire pipeline. The collaboration with Neurocrine Biosciences provides validation and financial support. However, the UQS Moat pillar rates this advantage as Weak, reflecting the early-stage nature of the company's competitive position.
What sector does XENE belong to?
XENE operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. It focuses on the neurology sub-segment, targeting rare and severe forms of epilepsy through ion-channel-modulating drug candidates.
Is XENE a growth stock or value stock?
XENE carries characteristics of a speculative growth stock — the market prices in future pipeline success — but the UQS Growth pillar is rated Weak and Valuation is Elevated. That combination suggests investors are paying a premium for growth that has not yet materialized in financial results.
Unlock Full XENE Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar breakdown for XENE
- ✓Access underlying financial metrics and trend data
- ✓Compare XENE against sector peers side by side
- ✓Screen for stronger-rated Healthcare stocks
- ✓Track pipeline-stage companies across the biotech universe
- ✓Get the full analyst-grade quality view in one place
Pro Analysis
XENE — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | 26.1 | 0.4 | 35.0 | 39.3 | 62.6 | 0.0 | -1.2 |
| Apr 2, 2026 | 27.3 | 0.4 | 35.0 | 39.3 | 70.3 | 0.0 | — |
XENE — Pillar Breakdown
Quality
— 0.4/100 (25%)Xenon Pharmaceuticals Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 39.3/100 (20%)Xenon Pharmaceuticals Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 62.6/100 (15%)Xenon Pharmaceuticals Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Xenon Pharmaceuticals Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 35/100 (25%)Xenon Pharmaceuticals Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for XENE.
Score Composition
Financial Data
More Stock Analysis
How is the XENE UQS Score Calculated?
The UQS (Unified Quality Score) for Xenon Pharmaceuticals Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Xenon Pharmaceuticals Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Xenon Pharmaceuticals Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.